Image

Breaking News

Featured image for “Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma”
05/30/2023

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

May 26, 2023 17:30 ET| Source: Iovance Biotherapeutics, Inc. Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
02/28/2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)–  The applications are based on results from the Phase 3 CheckMate -76K trial,…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update”
12/08/2022

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting”
11/11/2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma”
09/30/2022

Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma

(Source:Georgetown University Medical Center) Originally published Sep 27, 2022, Medical Life Sciences Giving immunotherapy before targeted therapy improves survival in…
Blog - Melanoma360
, 
Breaking News
Featured image for “Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%”
09/16/2022

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

(NEWS PROVIDED BY  Bristol Myers Squibb, September 16, 2022, ) Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the…
Blog - Melanoma360
, 
Breaking News
Featured image for “ESMO: TIL therapy improves on Yervoy in melanoma trial”
09/13/2022

ESMO: TIL therapy improves on Yervoy in melanoma trial

(NEWS PROVIDED BY  Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…
Blog - Melanoma360
, 
Breaking News
Featured image for “Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors”
09/12/2022

Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors

(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…
Blog - Melanoma360
, 
Breaking News
Featured image for “Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma”
09/11/2022

Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma

Neoadjuvant IO Boosts High-Risk Melanoma EFS Results from the phase 2 SWOG S1801 study show that for patients given pembrolizumab…
Blog - Melanoma360
, 
Breaking News
Featured image for “Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag”
07/22/2022

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag

(reprint from Business Wire, published: July 22, 2022) Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody…
Blog - Melanoma360
, 
Breaking News
05/30/2023

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

May 26, 2023 17:30 ET| Source: Iovance Biotherapeutics, Inc. Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date…
Featured image for “Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
02/28/2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)–  The applications are based on results from the Phase 3 CheckMate -76K trial,…
Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
12/08/2022

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
Featured image for “Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
11/11/2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
Featured image for “Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
09/30/2022

Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma

(Source:Georgetown University Medical Center) Originally published Sep 27, 2022, Medical Life Sciences Giving immunotherapy before targeted therapy improves survival in…
Featured image for “Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma”
Blog - Melanoma360
 | 
Breaking News
09/16/2022

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

(NEWS PROVIDED BY  Bristol Myers Squibb, September 16, 2022, ) Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the…
Featured image for “Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%”
Blog - Melanoma360
 | 
Breaking News
09/13/2022

ESMO: TIL therapy improves on Yervoy in melanoma trial

(NEWS PROVIDED BY  Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…
Featured image for “ESMO: TIL therapy improves on Yervoy in melanoma trial”
Blog - Melanoma360
 | 
Breaking News
09/12/2022

Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors

(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…
Featured image for “Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors”
Blog - Melanoma360
 | 
Breaking News
09/11/2022

Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma

Neoadjuvant IO Boosts High-Risk Melanoma EFS Results from the phase 2 SWOG S1801 study show that for patients given pembrolizumab…
Featured image for “Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma”
Blog - Melanoma360
 | 
Breaking News
07/22/2022

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag

(reprint from Business Wire, published: July 22, 2022) Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody…
Featured image for “Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag”
Blog - Melanoma360
 | 
Breaking News

Recent Posts

Featured image for “Meaning-Centered Psychotherapy: Finding Purpose in the Face of Cancer”
Jan. 14, 2025

Meaning-Centered Psychotherapy: Finding Purpose in the Face of Cancer

Featured image for “What Inspires Leading Melanoma Researchers? ”
Jan. 09, 2025

What Inspires Leading Melanoma Researchers? 

Featured image for “Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients”
Dec. 30, 2024

Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients

Featured image for “Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab”
Dec. 27, 2024

Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab

Featured image for “Navigating Melanoma Together: 2024 Podcast Wrap-Up”
Dec. 12, 2024

Navigating Melanoma Together: 2024 Podcast Wrap-Up

Filter by Tag